Overview
I am a hematology/oncology fellow and post-doctoral fellow in the National Clinician Scholars Program at Duke University School of Medicine. I envision a career as an oncologist, health services/outcomes, and equity researcher focused on addressing disparities in care for patients with hematologic malignancies from under-represented backgrounds. I am interested in understanding how epidemiology, patterns, quality, and cost of care impact healthcare delivery and outcomes in patients with hematologic malignancies from under-represented backgrounds, with particular attention to factors along the continuum of care, to ultimately guide the development of appropriate interventions to address inequities.
Current Appointments & Affiliations
House Staff
Medicine,
Clinical Science Departments
House Staff
Medicine, Medical Oncology,
Medicine
Recent Publications
Postpartum Readmission for Pregnancy-Associated Thrombotic Microangiopathy Is Associated With Poor Maternal Outcomes.
Journal Article J Clin Apher · February 2026 The postpartum period represents a high-risk interval for presentation with a pregnancy-associated thrombotic microangiopathy (TMA). Given the possibility of immune thrombotic thrombocytopenic purpura, postpartum TMA is typically treated with initiation of ... Full text Link to item CiteIron Deficiency Anemia is Associated With Gastric Intestinal Metaplasia in Patients With Helicobacter pylori Infection.
Journal Article Gastro Hep Adv · 2026 BACKGROUND AND AIMS: Despite acknowledgment of the relationship between iron deficiency anemia (IDA) and Helicobacter pylori, consensus is lacking on clinical practice implications. This study sought to examine the association of iron deficiency and anemia ... Full text Link to item CiteIn patients with suspected thrombotic thrombocytopenic purpura, what is the optimal time to therapeutic plasma exchange?
Journal Article Hematol Transfus Cell Ther · December 12, 2025 BACKGROUND: In patients with suspected immune thrombotic thrombocytopenic purpura, guidelines suggest that therapeutic plasma exchange should be initiated within eight hours. However, this time threshold may be difficult to attain. This study sought to ide ... Full text Link to item CiteRecent Grants
Experience of Veterans with Myeloproliferative Neoplasms
ResearchPrincipal Investigator · Awarded by American Society of Clinical Oncology · 2025 - 2026Exploring the impact of conditioning regimen selection on clinical outcomes and quality of life in
ResearchPI-Fellow · Awarded by American Society of Hematology · 2024 - 2026View All Grants